Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIXT Lixte Biotechnology Holdings Inc.

Closed Good Friday 04-17 16:00:00 EDT

1.13

-0.09

-7.72%

盘后1.18

+0.05+4.30%

16:00 EDT

High1.22	Low1.13	Vol458.00
Open1.22	D1 Closing1.23	Amplitude7.23%
Mkt Cap3.04M	Tradable Cap2.86M	Total Shares2.68M
T/O541.82	T/O Rate0.02%	Tradable Shares2.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LIXT","market":"US","secType":"STK","nameCN":"Lixte Biotechnology Holdings Inc.","latestPrice":1.1314,"timestamp":1744920000000,"preClose":1.226,"halted":0,"volume":458,"hourTrading":{"tag":"盘后","latestPrice":1.18,"preClose":1.1314,"latestTime":"16:00 EDT","volume":33,"amount":38.94,"timestamp":1744920002529},"delay":0,"floatShares":2523701,"shares":2684074,"eps":-1.594265,"marketStatus":"Closed Good Friday","change":-0.0946,"latestTime":"04-17 16:00:00 EDT","open":1.22,"high":1.22,"low":1.1314,"amount":541.8226,"amplitude":0.072268,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.594265,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1606280400000,"exchange":"NASDAQ","adjPreClose":1.226,"postHourTrading":{"tag":"盘后","latestPrice":1.18,"preClose":1.1314,"latestTime":"16:00 EDT","volume":33,"amount":38.94,"timestamp":1744920002529},"volumeRatio":0.09444857000472535},"requestUrl":"/m/hq/s/LIXT","defaultTab":"news","newsList":[{"id":"2522199370","title":"Lixte Biotechnology Provides Update on Progress With Proprietary Compound, Lb-100, to Treat Ovarian and Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522199370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522199370?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:30","pubTimestamp":1743078601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA2LVN0P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXTW","LIXT","BK4139"],"gpt_icon":0},{"id":"2522305561","title":"LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522305561","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522305561?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:30","pubTimestamp":1743078600,"startTime":"0","endTime":"0","summary":"-Started Two New Clinical Trials,Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer-. -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer Immunotherapies-. PASADENA, Calif, March 27, 2025  -- LIXTE Biotechnology Holdings, Inc.  , a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities.“LIXTE trials are underway for ovarian cancer at the M.D. Anderson Cancer Center and at Northwestern University, supported by GSK. Our colorectal trial, supported by F. Hoffmann-La Roche, is being conducted at the Netherlands Cancer Institute,” Mr. van der Baan added.LIXTE Biotechnology Holdings, Inc.is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lixte-biotechnology-provides-progress-proprietary-123000732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LIXT","PRGS","BK4213","BK4233","LU2065732104.USD","LB","LIXTW"],"gpt_icon":0},{"id":"2518740277","title":"BRIEF-Lixte Biotechnology terminates sales agreement with Wallachbeth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2518740277","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518740277?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 22:35","pubTimestamp":1741703732,"startTime":"0","endTime":"0","summary":"BRIEF-Lixte Biotechnology terminates sales agreement with Wallachbeth CapitalMarch 11  - Lixte Biotechnology Holdings Inc LIXT.O:LIXTE BIOTECHNOLOGY HOLDINGS INC - TERMINATES SALES AGREEMENT WITH WALLACHBETH CAPITALLIXTE BIOTECHNOLOGY HOLDINGS INC - SALES AGREEMENT TERMINATION EFFECTIVE MARCH 18, 2025Further company coverage: LIXT.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU07R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT"],"gpt_icon":0},{"id":"2514091901","title":"Lixte Adds NorthWestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514091901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514091901?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:30","pubTimestamp":1740490200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUAC5NW39:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","LIXTW","BK4139"],"gpt_icon":0},{"id":"2514350094","title":"LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514350094","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514350094?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:30","pubTimestamp":1740490200,"startTime":"0","endTime":"0","summary":"-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab --. PASADENA, CALIF., Feb. 25, 2025  -- LIXTE Biotechnology Holdings, Inc.  , a clinical stage pharmaceutical company, today announced it has added the Robert H. Lurie Comprehensive Cancer Center  of Northwestern University as a second site in a clinical trial combining the Company’s proprietary compound LB-100 with GSK’s Dostarlimab to treat ovarian clear cell cancer.Emily M. Hinchcliff, MD, MPH, will lead the clinical trial at Lurie Cancer Center, arenown Chicago-based National Cancer Institute-designated Comprehensive Cancer Center,which is located at Northwestern Memorial Hospital’s downtown medical campus. Patient recruitment is underway, and the first patient has been dosed.This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lixte-adds-northwestern-university-lurie-133000928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LIXTW","BK4139","LIXT","NWE","BK4208"],"gpt_icon":0},{"id":"2511224095","title":"Lixte Biotechnology Closes $1.1 Million Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2511224095","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511224095?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 00:02","pubTimestamp":1739462567,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology  said Thursday it closed a registered direct offering of 434,784 shares at $2.415 apiece for about $1.1 million in gross proceeds.The biotechnology company said it plans to use the net proceeds for working capital and other general corporate purposes.Lixte also said it issued unregistered warrants in a concurrent private placement to acquire up to 434,784 shares, with each warrant exercisable at $2.29 per share.Shares were down 2.4% in recent trading.Price: 1.66, Change: -0.04, Percent Change: -2.35","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2511524307","title":"Lixte Biotechnology announces closing of $1.05M registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2511524307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511524307?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 23:43","pubTimestamp":1739461424,"startTime":"0","endTime":"0","summary":"LIXTE Biotechnology (LIXT) announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-announces-closing-of-1-05m-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-announces-closing-of-1-05m-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["USAW.SI","NVIW.SI","QID","SQQQ","TSYW.SI","USJW.SI","MNQmain","LIXT","PSQ",".IXIC","BK4139","TQQQ","QLD","NQmain"],"gpt_icon":0},{"id":"2511352141","title":"Lixte Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2511352141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511352141?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 23:35","pubTimestamp":1739460900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA9CVQYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","LIXTW","BK4139"],"gpt_icon":0},{"id":"2510389718","title":"Lixte Biotechnology Announces $1.05 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2510389718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510389718?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 21:42","pubTimestamp":1739281343,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA7VNZQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXTW","BK4139","LIXT"],"gpt_icon":0},{"id":"2510381358","title":"LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2510381358","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510381358?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 21:42","pubTimestamp":1739281320,"startTime":"0","endTime":"0","summary":"PASADENA, CALIF., Feb. 11, 2025  -- LIXTE Biotechnology Holdings, Inc.  , a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants will have an exercise price of $2.29 per share and will be exercisable for five years from the date of issuance. The closing of the offering is expected to occur on or about February 12, 2025, subject to the satisfaction of customary closing conditions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lixte-biotechnology-announces-1-05-134200360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","LIXT","PSQ","IE00B3QW5Z07.USD","USJW.SI","NVIW.SI","IE00B64PRP62.GBP","SQQQ","IE00BGHQF748.EUR","QLD",".IXIC","NDAQ","MNQmain","LIXTW","USAW.SI","TQQQ","TSYW.SI","BK4585","BK4112","IE00BKPKM429.USD","LU2095319765.USD","QID","BK4588","LU2210149790.SGD","LU2210150020.SGD"],"gpt_icon":1},{"id":"2510815801","title":"Lixte Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510815801","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510815801?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 06:00","pubTimestamp":1739224800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA4WJCPQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139","LIXTW"],"gpt_icon":0},{"id":"2510619815","title":"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510619815","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510619815?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 06:00","pubTimestamp":1739224800,"startTime":"0","endTime":"0","summary":"PASADENA, CALIF., Feb. 10, 2025  -- LIXTE Biotechnology Holdings, Inc.  , a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission  of the Company’s Registration Statement on Form S-1 , as amended, originally filed on October 23, 2024 , as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lixte-biotechnology-submits-request-withdrawal-220000888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LIXTW","BK4139","LIXT"],"gpt_icon":0},{"id":"2494358648","title":"BRIEF-Lixte Biotechnology Holdings' Eric Forman Resigns As VP And COO Of Lixte Biotech Effective As Of Dec 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2494358648","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494358648?lang=en_us&edition=full_marsco","pubTime":"2024-12-28 05:13","pubTimestamp":1735333989,"startTime":"0","endTime":"0","summary":"BRIEF-Lixte Biotechnology Holdings' Eric Forman Resigns As VP And COO Of Lixte Biotech Effective As Of Dec 31Dec 27  - Lixte Biotechnology Holdings Inc LIXT.O:LIXTE BIOTECHNOLOGY HOLDINGS - ON DEC 23, ERIC FORMAN RESIGNS AS VP AND COO OF LIXTE BIOTECH EFFECTIVE AS OF DEC 31Further company coverage: LIXT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nFWN3NS060:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2494358583","title":"Lixte Biotechnology Holdings - on Dec 23, Eric Forman Resigns as Vp and COO of Lixte Biotech Effective as of Dec 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2494358583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494358583?lang=en_us&edition=full_marsco","pubTime":"2024-12-28 05:09","pubTimestamp":1735333782,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nFWN3NS060:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIXT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lixte.com","stockEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":-0.0544},{"period":"3month","weight":-0.5134},{"period":"6month","weight":-0.4013},{"period":"1year","weight":-0.6602},{"period":"ytd","weight":-0.4426}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.183375},{"month":2,"riseRate":0.714286,"avgChangeRate":0.106103},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.047366},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.120234},{"month":5,"riseRate":0.428571,"avgChangeRate":0.004396},{"month":6,"riseRate":0.571429,"avgChangeRate":0.067973},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.025571},{"month":8,"riseRate":0.428571,"avgChangeRate":0.094306},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.0075},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.001038},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.039775},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.154789}],"exchange":"NASDAQ","name":"Lixte Biotechnology Holdings Inc.","nameEN":"Lixte Biotechnology Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lixte Biotechnology Holdings Inc.,LIXT,Lixte Biotechnology Holdings Inc.股票,Lixte Biotechnology Holdings Inc.股票老虎,Lixte Biotechnology Holdings Inc.股票老虎国际,Lixte Biotechnology Holdings Inc.行情,Lixte Biotechnology Holdings Inc.股票行情,Lixte Biotechnology Holdings Inc.股价,Lixte Biotechnology Holdings Inc.股市,Lixte Biotechnology Holdings Inc.股票价格,Lixte Biotechnology Holdings Inc.股票交易,Lixte Biotechnology Holdings Inc.股票购买,Lixte Biotechnology Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}